QR kód

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer

Whether neoadjuvant therapy confers a survival benefit in advanced prostate cancer (PCa) remains uncertain. The primary endpoints of previous retrospective and phase II clinical studies that used neoadjuvant therapy, including androgen deprivation therapy combined with new-generation androgen recept...

Celý popis

Uloženo v:
Hlavní autoři: Yongbao Wei, Ruochen Zhang, Dewen Zhong, Zhensheng Chen, Gen Chen, Minggen Yang, Le Lin, Tao Li, Liefu Ye, Lili Chen, Qingguo Zhu
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2023-10-01
Edice:Frontiers in Pharmacology
Témata:
prostate cancer
androgen deprivation therapy
apalutamide
neoadjuvant therapy
radical prostatectomy
On-line přístup:https://www.frontiersin.org/articles/10.3389/fphar.2023.1284899/full
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky